UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $22.09 Million Stock Position in Ralliant Corporation $RAL

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in shares of Ralliant Corporation (NYSE:RAL) by 39.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 299,980 shares of the company’s stock after selling 192,964 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Ralliant were worth $22,088,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Allworth Financial LP increased its position in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares in the last quarter. Rothschild Investment LLC boosted its holdings in Ralliant by 98.1% in the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after acquiring an additional 303 shares in the last quarter. UMB Bank n.a. boosted its holdings in Ralliant by 49.6% in the fourth quarter. UMB Bank n.a. now owns 983 shares of the company’s stock worth $50,000 after acquiring an additional 326 shares in the last quarter. Maryland State Retirement & Pension System grew its stake in Ralliant by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock valued at $1,117,000 after acquiring an additional 329 shares during the period. Finally, Dunhill Financial LLC bought a new stake in shares of Ralliant during the second quarter valued at approximately $25,000.

Insider Activity

In other news, CEO Tamara Newcombe sold 12,936 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the transaction, the chief executive officer owned 251,967 shares in the company, valued at $18,088,710.93. The trade was a 4.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen Bick sold 6,062 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the transaction, the senior vice president directly owned 31,668 shares in the company, valued at approximately $2,280,096. This represents a 16.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on RAL. Wall Street Zen lowered Ralliant from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 30th. Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Evercore began coverage on shares of Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective on the stock. Citigroup raised their price objective on shares of Ralliant from $81.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Oppenheimer lifted their price objective on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $75.70.

Ralliant Trading Up 1.1%

Shares of Ralliant stock opened at $63.46 on Friday. The company has a market capitalization of $7.02 billion, a P/E ratio of -5.85, a price-to-earnings-growth ratio of 2.33 and a beta of 1.54. The stock has a fifty day simple moving average of $67.52 and a 200 day simple moving average of $57.10. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $75.41. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The firm had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, sell-side analysts anticipate that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant’s dividend payout ratio (DPR) is presently -1.84%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.